Liver/Biliary

Advance Against Hepatitis B

Long-term treatment with entecavir, an inhibitor of hepatitis B virus (HBV) replication, reduces cirrhosis and fibrosis in patients with chronic hepatitis B infection, report Eugene Schiff et al. in the March issue of Clinical Gastroenterology and Hepatology.  Patients with chronic hepatitis B can develop liver fibrosis or cirrhosis and have

Read more

Same Liver, New Location

Functional liver tissue can be grown in lymph nodes of mice and rescue them from lethal hepatic disease, reports Toshitaka Hoppo et al. in the February issue of Gastroenterology—lymph nodes therefore might someday be used as sites for hepatocyte transplantation in patients with end-stage liver disease. Many patients with chronic hepatic

Read more

What is the Best Strategy for Treating Pediatric Autoimmune Hepatitis?

Immunosuppressant therapy causes permanent recovery from liver failure in most children with autoimmune hepatitis (AIH), reports Miriam Cuarterolo et al. in the February issue of Clinical Gastroenterology and Hepatology. AIH is a progressive, inflammatory liver disease that predominantly affects girls before puberty. Without treatment, it progresses to cirrhosis and liver

Read more

Unsafe at Any Speed?

Driving privileges of people with hepatic encephalopathy (HE) should be restricted until they demonstrate that they are safe on the road, according to Stanley Martin Cohen et al. in the February issue of Clinical Gastroenterology and Hepatology. Because there are few laws about which patients with HE or other mental

Read more

Fibrosis in Patients with HIV and Hepatitis C

HIV infection does not speed the progression of fibrosis in patients with Hepatitis C, according to findings from Richard Sterling et al. in the December issue of Clinical Gastroenterology and Hepatology. Sterling et al. compared liver biopsies taken from more than 300 patients with HIV/HCV co-infection and more than 200

Read more

Coffee, Beyond Caffeine

Coffee—caffeinated or decaffeinated—protects liver and gastrointestinal cells from toxic compounds, according to Sandra Kalthoff et al. in the November issue of Gastroenterology. In many epidemiology studies, coffee consumption reduced the risk of inflammation, chronic liver diseases, hepatocellular carcinoma (HCC), and other GI disorders. Its mechanisms are unclear, however, because coffee

Read more

Are Biopsies Safe for Patients with Advanced Liver Disease?

Liver biopsies are relatively safe and well tolerated among patients with advanced chronic hepatitis C, based on data from the HALT-C trial.  Liver biopsy analysis provides information for diagnosis and planning of treatment strategies for patients with acute and chronic liver diseases, such as chronic hepatitis C infection. However, biopsies

Read more

Cadaveric Liver Cells for Transplantation?

The only effective treatment for liver failure is transplantation, which is limited by the short supply of organ donors. A study by Laura Erker et al. in the September issue of Gastroenterology reports that liver cells from human cadavers might someday be used for transplantation. Erker et al. showed that

Read more

Marking the Course of Hepatitis B

It is a challenge to monitor the course of chronic hepatitis B. Patients still carry the Hepatitis B surface antigen (HBsAg) but have varying levels of viral DNA, HBeAg, and liver inflammation—and remain at risk for developing hepatocellular carcinoma (HCC). Two papers in this month’s issue of Gastroenterology investigate Hepatitis

Read more

How should we assess quality of cirrhosis care?

Insurance companies and government agencies attempt to assess healthcare quality to develop quality-based reimbursement models. It is a challenge to define and measure quality of care, however, especially for complex, chronic diseases such as cirrhosis. Two studies in the August issue of Clinical Gastroenterology and Hepatology (CGH) identify tools for

Read more